cervical esophageal cancer
Conditions
Interventions
Concurrent chemoradiotherapy with SIB-IMRT (60Gy (prophylactin LN region: 48Gy)/30fr.) and two cycles of chemotherapy (5-FU 700 mg/m2, day 1-4, CDDP 70 mg/m2, day1, q4w) follwed by two cycles of adjuv
Sponsors
Japanese Radiation Oncology Study Group(JROSG)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: i) cervical esophageal cancer with pathologically proven squamous cell carcinoma or adenosquamous cell carcinoma; ii) Clinical stage II-III or IV with supraclavicular LN metastasis (UICC 7th edition, 2009) ; iii) Aged 20 to 75 years old; iv) ECOG PS of 0 to 2; v) No prior chemotherapy against any malignancies; vi) No prior radiotherapy against head and neck or chest region; vii) Screening and diagnosis by an otorhinolaryngologist; viii) Sufficeient organ functions; ix) Written informed consent.
Exclusion criteria
Exclusion criteria: i) Simultaneous or metachronous (within 5 years) double cancers; ii) Systemic infections disease; iii) Body temperature of 38C or higher; iv) Women during pregnancy or breast-feeding; v) Psychiatric disease and/or depression; vi) Continuous systemic steroids medication; vii) HBs antigen positive; viii) Uncontrollable diabetes mellitus; ix) Uncontrollable hypertension; x) Myocardial infarction within 6 months or unstable angina pectoris; xi) Serious complications (interstitial pneumonia, pulmonary fibrosis, COPD, heart failure, etc.); xii) cerebrovasucular disease within 6 months; xiii) Histoty of collagen diseases; xiv) History of surgery of esophagus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3 year overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| 3 year progeression-free survival, 3y esophagus preservation rate, 3y larynx preservation rate, early and late adverse event rates | — |
Countries
Japan
Contacts
Public ContactSatoshi Itasaka
JROSG 12-1 Coordinating Office Department of Radiation Oncology, Kurashiki Central Hospital
Outcome results
None listed